Title:
COMPOSITIONS AND METHODS FOR TARGETED ENZYMATIC RELEASE OF CELL REGULATORY COMPOUNDS
Document Type and Number:
WIPO Patent Application WO2001002020
Kind Code:
A3
Abstract:
Novel pro-drugs and methods for their use to alter the growth and biological characteristics of living cells, tissues, or whole organisms are described. The methods allow for selective activation of the pro-drugs at or near transformant host cells expressing a gene for an enzyme that activates the pro-drugs. Pro-drugs according to a preferred embodiment of the invention are conjugates of a bioactive compound and a chemical group that is capable of being cleaved from the bioactive compound by action of an enzyme. Methods according to this invention include: (a) introducing into targeted cells a gene encoding an enzyme and (b) administering a pro-drug, wherein the enzyme releases the pro-drug from conjugation. In a preferred embodiment of the invention, the gene encoding the enzyme is a marker gene.
More Like This:
Inventors:
NALEWAY JOHN (US)
HOWARD RACHEL (US)
HOWARD RACHEL (US)
Application Number:
PCT/US2000/015156
Publication Date:
July 19, 2001
Filing Date:
June 01, 2000
Export Citation:
Assignee:
MARKER GENE TECHNOLOGIES INC (US)
NALEWAY JOHN (US)
HOWARD RACHEL (US)
NALEWAY JOHN (US)
HOWARD RACHEL (US)
International Classes:
A61K47/48; C07H15/04; C07H15/203; C07H15/24; C07H15/244; C07H15/252; C07H15/26; C07H19/06; C07J17/00; C12N1/21; C12N15/87; A61K48/00; (IPC1-7): A61K48/00; C12N9/38; C12N9/02; C12N9/86; C07H15/24; C07H15/26; C07H15/203; C07H15/252; C07H15/244; C07H19/073
Domestic Patent References:
| WO1998030709A2 | 1998-07-16 | |||
| WO1996015435A2 | 1996-05-23 |
Other References:
DATABASE CANCERLIT US NATIONAL CANCER INSTITUTE; D. FARQUHAR ET AL.,: "Antitumor galactoside prodrugs (Meeting abstract)", XP002153500
DATABASE BIOSIS BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; D. FARQUHAR ET AL.,: "Antitumor galactoside prodrugs", XP002153501
DATABASE CANCERLIT US NATIONAL CANCER INSTITUTE; F. MARINI ET AL.,: "E. coli LacZ as a suicide gene for anticancer prodrug activation (Meeting abstract)", XP002153502
DATABASE PUBMED NATIONAL LIBRARY OF MEDICINE (NCBI); WA DENNY ET AL.,: "The design of selectively-activated anti-cancer prodrugs for use in antibody-directed and gene-directed enzyme-prodrug therapies", XP002153503
DATABASE BIOSIS BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; E. BAKINA ET AL.,: "Intensely cytotoxic anthracycline prodrugs : galactosides.", XP002153504
DATABASE BIOSIS BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; D. FARQUHAR ET AL.,: "Antitumor galactoside prodrugs", XP002153501
DATABASE CANCERLIT US NATIONAL CANCER INSTITUTE; F. MARINI ET AL.,: "E. coli LacZ as a suicide gene for anticancer prodrug activation (Meeting abstract)", XP002153502
DATABASE PUBMED NATIONAL LIBRARY OF MEDICINE (NCBI); WA DENNY ET AL.,: "The design of selectively-activated anti-cancer prodrugs for use in antibody-directed and gene-directed enzyme-prodrug therapies", XP002153503
DATABASE BIOSIS BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; E. BAKINA ET AL.,: "Intensely cytotoxic anthracycline prodrugs : galactosides.", XP002153504
Download PDF:
Previous Patent: CONTROL OF GENE EXPRESSION
Next Patent: A RADIOLABELED MAMMALIAN TACHYKININ PEPTIDE ANALOGUE
Next Patent: A RADIOLABELED MAMMALIAN TACHYKININ PEPTIDE ANALOGUE